OTCMKTS:BAYRY

6.74
0.00 (0.00%) 1d
0

Related posts

Nervous markets await Nvidia
Investor Insights

This summary was created by AI, based on 2 opinions in the last 12 months.

Bayer AG, with the ticker BAYRY-OTC, has recently seen some positive momentum due to a favorable court ruling regarding its Monsanto division, which dismisses claims about its Roundup products potentially increasing cancer risk. This legal win has led to a significant uptick in stock price, reflecting a jump of over 10% on that news. Recent quarterly financial results also painted a positive picture, surpassing earnings expectations and maintaining full-year guidance, suggesting a resilient performance despite challenges. However, while the stock appears cheap at 5.5 times forward earnings, experts express caution due to high debt levels and an overall low growth forecast, which tempers their enthusiasm. The mixed sentiment is underscored by the experience of another expert who, having sold the stock after a substantial decline tied to ongoing litigation issues, highlights the necessity of risk management in volatile scenarios.

Consensus
Cautious
Valuation
Undervalued
DON'T BUY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

There was some positive news on the 16th, after a US court ruled in favor of its Monsanto business in a lawsuit alleging that BAYRY's Roundup weedkiller products increase the risk of cancer. These claims were dismissed and the stock jumped over 10% that day. Recent quarterly results were positive and it beat on earnings and affirmed full-year guidance. It continues to be very cheap at 5.5x forward earnings but growth is not expected to be high while debt is also very high. We continue to not be overly excited here. 
Unlock Premium - Try 5i Free

PAST TOP PICK
(A Top Pick Jul 31/23, Down 51%)

He sold it last February. When he bought it was down 50% on the Mansanto litigation. He dumped up, classic risk management.

TOP PICK

It is priced at 50 cents on the dollar compared to its peers. In 2018 it bought Monsanto and the Roundup litigation halved the company. However it is being dealt with. It has three new drugs on the pharma side, one with no near term competitors when it comes off patent. It will probably spin out the herbicide business and sits at a very attractive price.    Buy 18  Hold 8  Sell 1

DON'T BUY
Their last quarter wasn't great; there was some positive news in their pharma pipeline. They sold assets from BASF to reduce net debt, which is now at Euros 36.5 billion. The debt-to-cash flow is still high, so they have a low credit rating. Their chemical side isn't growing. EPS are down 18%, which pressured the stock. JNJ has a better phrama pipeline and credit rating.
BUY ON WEAKNESS

On these big Chemicals you are always best to wait for an opportunity to get in. There isn't an urgent rush. This company is a monstrously big company.

DON'T BUY
Into pharmaceuticals and chemicals. Things seem to be moving along very well. Getting a little overpriced at these levels.
Showing 1 to 6 of 6 entries
  • «
  • 1
  • »

Bayer AG(BAYRY-OTC) Rating

Ranking : 3 out of 5

Star iconStar iconStar iconStar empty iconStar empty icon

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 2

Stockchase rating for Bayer AG is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Bayer AG(BAYRY-OTC) Frequently Asked Questions

What is Bayer AG stock symbol?

Bayer AG is a American stock, trading under the symbol BAYRY-OTC on the US OTC (BAYRY). It is usually referred to as OTC:BAYRY or BAYRY-OTC

Is Bayer AG a buy or a sell?

In the last year, 2 stock analysts published opinions about BAYRY-OTC. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Bayer AG.

Is Bayer AG a good investment or a top pick?

Bayer AG was recommended as a Top Pick by on . Read the latest stock experts ratings for Bayer AG.

Why is Bayer AG stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Bayer AG worth watching?

2 stock analysts on Stockchase covered Bayer AG In the last year. It is a trending stock that is worth watching.

What is Bayer AG stock price?

On 2025-05-02, Bayer AG (BAYRY-OTC) stock closed at a price of $6.74.